Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03947450
Other study ID # IRB00192461
Secondary ID W81XWH-18-2-0055
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 5, 2019
Est. completion date April 1, 2028

Study information

Verified date June 2024
Source Johns Hopkins University
Contact Ruizhi Wang, MPhil
Phone 410-502-7546
Email rwang53@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a clinical trial testing the safety and efficacy of volar fibroblast (skin cells from the palm or sole) injections for thickening the epidermal (skin) layer at the stump site in people with below the knee amputations. The study will enroll adults seen at Johns Hopkins.


Description:

This study is a clinical trial testing the safety and efficacy of volar fibroblast (skin cells from the palm or sole) injections for thickening the epidermal (skin) layer at the stump site in people with below the knee amputations. The study will enroll adults seen at Johns Hopkins. The investigators have demonstrated that injection of fibroblasts (from the palm or sole) is safe in healthy adults and potentially enhances palm or sole features in skin cells in areas other than the palm and sole. In a prior study, healthy adults injected with fibroblasts (from the palm or sole) experienced more firm skin at the injection site. The objective of this study is to determine if fibroblast (from palm or sole) injections are safe and effective at increasing epidermal thickness and skin firmness at the stump site in below the knee amputees. Outcomes are assessed via questionnaires, non-invasive imaging devices, and non-invasive skin firmness measuring devices. Injections will be targeted to the entire stump (unless determined otherwise by the PI and participant), including pressure intolerant areas of the skin that come into contact with the prosthetic socket, a region that is prone to skin irritation and breakdown, We will evaluate the most effective approach to administering this intervention via injections to the entire stump and the safety and effectiveness of whole stump injections and their effects on prosthesis use, skin breakdown, quality of life, and activity level. The investigators hope that information from this study will help with problems like skin breakdown in patients with amputations and prosthetics. The skin at the stump was not meant to withstand the pressure and friction of prosthetics and this study is the first step in trying to convert stump skin to palm/sole-like skin.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date April 1, 2028
Est. primary completion date April 1, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: Patients interested in study participation must meet all of the following inclusion criteria: - May be male or female - Must be between 18 years and 65 years of age - Must have a below the knee amputation. - Must be using a prosthetic for the vicinity of 3 months or have had osteo-integration of a prosthetic in place for 1 month. - In the opinion of the investigator, must be medically able to undergo the administration of study material determined by laboratory tests obtained within 7 days before baseline for which the investigator identified no clinically significant abnormality. - Be able to comprehend the informed consent document and provide consent for participation - Females of childbearing potential must: - have a negative pregnancy test at screening - agree to not become pregnant or breastfeed for the period of the study through 1 month after completion of the study - be willing to use a reliable form of contraception during the study - Be willing and able to comply with the scheduled visits, biopsy/injection procedures, wound care instructions treatment plan, and other study procedures for the duration of the study. Exclusion Criteria: Patients meeting any of the following criteria will be ineligible for study participation: - A skin erosion deeper than the skin dermis. - Having received any investigational drug within 30 days prior to study entry - An allergy history to any study materials including local anesthetic, dimethyl sulfoxide, human albumin, or bovine constituents, hetastarch, or EMLA (lidocaine 2.5% and prilocaine 2.5%). - Pregnant, lactating, or trying to become pregnant - A history of keloid formation - Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I/II, Hepatitis B, Hepatitis C). Biopsies taken from individuals with infections that are not allowed to enter the cell therapy core will make it such that these individuals cannot participate. - Specifically we will exclude those with autoimmune diseases affecting the skin such as lupus. - Presence of necrotic ischemic tissue on any stump ulcers, and/or capillary refill on stump skin of greater than 3 seconds - Active infection of the residual limb. - Active smoker during the study - We will also exclude those who are on chronic immunosuppressive therapies such as oral steroids, but also those on chronic topical steroids in the area of investigation. - Recent amputee who has not yet been approved to use a prosthetic. - Use of a prosthetic for less than 3 months. - Amputees with neuromas of the terminal limb within the last 3 months. - Known bleeding disorder. - For those receiving Bellafill/collagen skin test: history of serious allergy, such as anaphylaxis. - For whole stump injections: Have a history of congenital or idiopathic methemoglobinemia, glucose-6-phosphate deficiencies, or use of medications associated with drug-induced methemoglobinemia. (specifically: Sulfonamides, Acetaminophen, Acetanilid, Aniline dyes, Benzocaine, Chloroquine, Dapsone, Naphthalene, Nitrates and Nitrites, Nitrofurantoin, Nitroglycerin, Nitroprusside, Pamaquine, Para-aminosalicylic acid, Phenacetin, Phenobarbital, Phenytoin, Primaquine, or Quinine.)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Autologous Skin Fibroblasts
The site or whole stump will be injected with autologous fibroblasts
Placebo
The site or whole stump will be injected medium only without autologous skin fibroblasts

Locations

Country Name City State
United States Department of Dermatology at Johns Hopkins University Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety as assessed by number of hospitalizations To determine the safety of the use of autologous volar fibroblasts to reprogram non-volar to volar-like epidermis with larger cytoplasmic area in human participants. The investigators will measure the numbers of hospitalizations which are related to the study. The occurrence of any study related hospitalization will be counted as one. 12 months
Secondary Change in amount of skin breakdown as assessed by ulceration measurement Skin breakdown as assessed by ulceration measurement: The investigators will measure areas of skin breakdown on the terminal limb to see if the areas injected with volar fibroblasts have influenced skin healing. The unit of measurement is in millimeters. Pre and post cell-injection measurements will be compared. Baseline, 1 month
See also
  Status Clinical Trial Phase
Completed NCT04924036 - Qbrexza Cloths for Hyperhidrosis of Amputation Sites Phase 2
Recruiting NCT04839497 - Multicenter Trial Evaluating the Safety and Efficacy of Autologous Volar Fibroblast Injection Into the Terminal Limb of Amputees. Phase 2
Recruiting NCT04212299 - Transfemoral Socket Design and Muscle Function N/A
Completed NCT03733054 - Understanding Prosthetic Needs and Outcomes in Women Veterans With Amputation
Completed NCT03651830 - A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations N/A
Recruiting NCT04725006 - Sensory Responses to Dorsal Root Stimulation N/A
Not yet recruiting NCT06007885 - Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention. N/A
Not yet recruiting NCT04936789 - Clinical Feasibility of the IMES Transradial Prosthesis N/A
Completed NCT01155024 - Clinical Evaluation of Direct Manufactured Prosthetic Sockets Phase 2
Completed NCT00663663 - Telephone Intervention for Pain Study (TIPS) N/A
Terminated NCT00778856 - Hand Transplantation for the Reconstruction of Below the Elbow Amputations N/A
Recruiting NCT00388752 - Acupuncture for the Treatment of Phantom Limb and Residual Limb Pain After Amputation Phase 1
Active, not recruiting NCT03374319 - Somatotopic Configuration of Distal Residual Limb Tissues in Lower Extremity Amputations N/A
Completed NCT05542901 - Comparison of Joint Position Sense in Diabetic and Traumatic Transtibial Amputees N/A
Completed NCT05161364 - Kinetic Analysis Due to Foot Dysfunction
Recruiting NCT06194838 - Clinical Outcomes With Non-Powered vs. Powered Prosthetic Knees by K2-level Amputees N/A
Completed NCT03570788 - HRQoL Among Patients Amputated Due to Peripheral Arterial Disease
Completed NCT05778799 - Physical Activity and Sports for People With Special Needs
Recruiting NCT04804150 - Daily Socket Comfort in Transtibial Amputee With an Active Vacuum Suspension System N/A
Terminated NCT03259386 - Movement and Sensation for Advanced Prosthetic Hands